Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Chugai Pharmaceutical : Announces 2021 3rd Quarter Results

10/22/2021 | 04:14am EST

Chugai Announces 2021 3rd Quarter Results

  • Record-highrevenues and core operating profit for the third quarter at ¥677.5 billion (+17.5%) and ¥290.7 billion (+25.4%), respectively
  • Forecasts for FY2021 raised following the strong nine-month results
  • Clinical development started for the first mid-size molecule project LUNA18. The new modality expected as the third pillar of Chugai's drug discovery technology
  • Regulatory application for Ronapreve filed in Japan for line extensions relating to COVID-19

TOKYO, October 22, 2021 --Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced its financial results for the third quarter of fiscal year 2021.

"We achieved robust double-digit growth in both revenues and profits in the nine months under review. This was due to significant increases in both domestic and overseas sales, driven by new products and mainstay products, as well as continued growth in royalty income. As a result, we raised our full year forecast for FY2021. In terms of R&D, I am very pleased that our first mid-size molecule project, LUNA18, has entered the clinical development phase. Mid-size molecule drugs are expected to become the third modality to drive our future growth. Concerning COVID-19, we have filed Ronapreve® for subcutaneous administration and the additional indications of treatment for asymptomatic patients and prophylaxis. In order to satisfy unmet medical needs through innovation, we will continue pursuing world- leading science and technology to contribute to patients awaiting treatments." said Dr. Osamu Okuda, Chugai's President and CEO.

[Third quarter results for 2021]

Revenues and Core operating profit increased by approximately 17% and 25%, respectively, for the third quarter (nine months, Core-basis), mainly due to increases in sales and royalty and profit-sharing income.

Revenues increased by approximately 20% in total since sales, which recorded flat year-on-year growth for the first half, turned to double-digit growth. Domestic sales increased by double digits as the strong oncology field grew further with a mainstay product Tecentriq® maintaining high growth despite the NHI price revision in August this year, and the contribution of a new product Polivy®. In the primary field, sales increased approximately 30% after reporting a decrease by roughly 10% in the first half. The growth was driven by new products, with the supply of Ronapreve to the government and the market penetration of Enspryng®, and double-digit growth of mainstay products, Actemra® and Hemlibra®. Overseas sales recovered growth and increased by approximately 10% as the further growth of Hemlibra outweighed the decrease in the sales of Actemra. Royalties and other operating income increased by approximately 20% mainly due to increases in royalty and profit-sharing income related to Hemlibra, despite a continued

decrease in other operating income resulting from one-time income.

Cost to sales ratio improved by 1.2% points year-on-year to 41.9%, mainly due to an increase in the proportion of in-house products including Hemlibra. Operating expenses increased approximately by 10% as research and development, marketing and distribution, and general and administration expenses all increased. Research and development expenses increased by double digits, continued from the first half, associated with the progress of projects. The increases in marketing and distribution expenses were affected by last year's decrease in activities due to the spread of the COVID-19. General and administration expenses increased owing to the enterprise tax and various expenses. As a result, core operating profit increased by approximately 25%.

The Company also made good progress in research and development. Its first mid-size molecule project, LUNA18, has entered the clinical development phase. Chugai has been focusing on mid-size molecule drugs as a new modality to constitute the mainstay for driving its medium-tolong-term growth. LUNA18 is an oral cyclic peptide RAS inhibitor, and a Phase I clinical trial has been initiated for solid tumors. As for other in-house projects, Chugai has started development of Enspryng in generalized Myasthenia Gravis (gMG), initiating a Phase III clinical trial.

In the efforts to develop treatments for COVID-19, Chugai filed an application for the antibody cocktail Ronapreve, which had received Special Approval in July. The filing is to obtain approval for additional indications for prophylaxis of COVID-19 and treatment of asymptomatic COVID-19, and additional subcutaneous administration. In addition, an application for approval was filed in Europe for Actemra for an additional indication of COVID-19 pneumonia.

[Revision of Full-Year Forecast for 2021]

Chugai raised forecasts (Core-basis) for FY2021 following the strong nine-month results. Regarding domestic sales, the sales forecast attributable to the supply of Ronapreve to the government, which was not expected at the beginning of the fiscal year, has been included, and the progress and revised assumptions have been reflected for each product including Avastin® and Tecentriq, which are progressing ahead of the initial forecast. The forecast for overseas sales has been revised upward reflecting that sales of Actemra and Hemlibra should exceed the original forecast. Royalties and other operating income have been also revised upward. As a result, the revenues have been raised to ¥970 billion, an increase of ¥170 billion from the initial forecast. Operating profit forecast has been revised to ¥400 billion, up ¥80 billion from the initial forecast, taking into account a higher cost to sales ratio due to a change in the product mix, and increases in some expenses including the foreign exchange effects.

2 / 4

In accordance with the revision of the financial forecast, year-end dividends forecast was also revised to an undecided value. Reflecting the significant changes in the profit structures, year-end dividends will be decided based on the Company's dividend policy* after the fiscal year ends.

*Regarding income distribution, taking into account the strategic funding needs and earning prospects, Chugai aims for a consolidated dividend payout ratio of 45% on average in comparison with Core EPS to provide a stable allocation of profit to all shareholders.

[2021 3rd quarter results]

Billion JPY

2021

2020

% change

Jan - Sep

Jan - Sep

Core results

Revenues

677.5

576.5

+17.5%

Sales

538.7

464.8

+15.9%

Royalties and other operating income

138.8

111.7

+24.3%

Operating profit

290.7

231.9

+25.4%

Net income

209.7

165.6

+26.6%

IFRS results

Revenues

677.5

576.5

+17.5%

Operating profit

282.8

227.3

+24.4%

Net income

204.2

162.4

+25.7%

[Sales breakdown]

Billion JPY

2021

2020

% change

Jan - Sep

Jan - Sep

Sales

538.7

464.8

+15.9%

Domestic sales

362.6

303.2

+19.6%

Oncology

191.1

169.4

+12.8%

Primary

171.6

133.8

+28.3%

Overseas sales

176.0

161.6

+8.9%

3 / 4

[Forecasts for 2021 Jan-Dec]

Revised

Original

Growth vs

Growth vs

Billion JPY

forecast on

forecast on

original forecast

2020 actual

Oct 22

Feb 4

Core-basis

Revenues

970.0

800.0

+170.0

+183.1

+23.3%

Sales

781.5

631.0

+150.5

+148.2

+23.4%

Royalties and other

188.5

169.0

+19.5

+34.9

operating income

+22.7%

Operating profit

400.0

320.0

+80.0

+92.1

+29.9%

[Progress in R&D activities from Jul 27th, 2021 to Oct 22nd, 2021]

About Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its decision to apply IFRS. Core results are the results after adjusting non-Core items to IFRS results, and are consistent with the Core concept disclosed by Roche. Core results are used by Chugai as an internal performance indicator, for explaining the underlying business performance both internally and externally, and the basis for payment- by-results such as a return to shareholders.

Trademarks used or mentioned in this release are protected by law.

###

4 / 4

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 22 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2021 08:13:14 UTC.


ę Publicnow 2021
All news about CHUGAI PHARMACEUTICAL CO., LTD.
12/01CHUGAI PHARMACEUTICAL : Launches a New Educational Website “So-Zo LABO” Aiming..
PU
11/26Chugai Pharmaceutical Co. - Anti Cancer Agent Herceptin Approved for Additional Indicat..
AQ
11/25CHUGAI PHARMACEUTICAL : Anti-Cancer Agent Herceptin Approved for Additional Indication of ..
PU
11/23Beijing IP Court To Hear China's First Case Of Patent Linkage
AQ
11/18CHUGAI PHARMACEUTICAL : Personnel Changes
PU
11/18CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
11/16CHUGAI PHARMACEUTICAL : Atea Announces Update on Collaboration with Roche for AT-527
PU
11/16Chugai Continuously Selected in the 'DJSI World,' a Global ESG Investment Index
AQ
11/16CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for FoundationOne CDx Cancer Genomic P..
PU
11/16CHUGAI PHARMACEUTICAL : Hosted Discussion Series to Drive Quality Cancer Care in Developin..
PU
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD.
More recommendations
Financials
Sales 2021 975 B 8 624 M 8 624 M
Net income 2021 292 B 2 585 M 2 585 M
Net cash 2021 469 B 4 152 M 4 152 M
P/E ratio 2021 20,4x
Yield 2021 1,87%
Capitalization 5 975 B 52 902 M 52 851 M
EV / Sales 2021 5,65x
EV / Sales 2022 5,42x
Nbr of Employees 7 555
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 3 634,00 JPY
Average target price 4 808,46 JPY
Spread / Average Target 32,3%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD.-33.96%52 902
JOHNSON & JOHNSON-0.92%410 501
ROCHE HOLDING AG16.39%337 091
PFIZER, INC.45.97%301 579
NOVO NORDISK A/S65.17%243 741
ELI LILLY AND COMPANY46.91%224 871